PDCD1 and neoplasm: Second, we wanted to investigate whether Glo1/MG pathway might be involved in the refractoriness of this neoplasia to PD-L1/PD-1-based immunotherapy, with a particular interest on the PD-L1-directed monoclonal antibody, atezolizumab.